EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Insilico discovery of novel Phosphodiesterase 4 (PDE4) inhibitors for the treatment of psoriasis: Insights from computer aided drug design approaches

Abdullah R Alanzi iD, Mohammed S Alsalhi, Ramzi A Mothana, Jawaher H Alqahtani, Moneerah J Alqahtani

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0305934 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Abdullah R Alanzi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Phosphodiesterase 4 Inhibitors, Psoriasis, Molecular Docking Simulation, Cyclic Nucleotide Phosphodiesterases, Type 4. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psoriasis is chronic immune-mediated inflammatory disorder characterized by various comorbidities, erythematous plaques with silvery scale which can lead to psoriatic arthritis. The phosphodiesterase 4 (PDE4) protein is a potential drug target to control Psoriasis. In the current study, pharmacophore-based virtual screening of Diversity library of ChemDiv database was first performed, and then the screened hits were docked to the active site of PDE4 to choose the best binding modes. Forty-six hits generated during the virtual screening were prepared and docked to the PDE4 receptor by SP docking module of glide. The binding affinities of the selected hits were calculated by molecular docking and based on the affinities, ten hits were selected for the bioactivity scores prediction and ADMET analysis. Based on the ADMET profiling, four hits D356-2630, C700-2058, G842-0420 and F403-0203 were processed to MD simulations for stability analysis. The outcomes showed that these compounds showed strong binding with proteins with better binding free energies. Based on the results of our study, we proposed that these hits can function as lead in the biological assays and in vitro studies are required to develop the novel drug candidates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphodiesterase 4 InhibitorsPsoriasisMolecular Docking SimulationCyclic Nucleotide Phosphodiesterases, Type 4Drug DesignHumansMolecular Dynamics SimulationComputer-Aided DesignDrug DiscoveryProtein BindingCatalytic Domain

Substanzen

Phosphodiesterase 4 InhibitorsCyclic Nucleotide Phosphodiesterases, Type 4

Autor:innen und Institutionen

  • Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
  • Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

ORCID-Profile: Abdullah R Alanzi

Zitieren

APA

Alanzi, A. R., Alsalhi, M. S., Mothana, R. A., Alqahtani, J. H., & Alqahtani, M. J. (2024). Insilico discovery of novel Phosphodiesterase 4 (PDE4) inhibitors for the treatment of psoriasis: Insights from computer aided drug design approaches. PLOS ONE. https://doi.org/10.1371/journal.pone.0305934

Vancouver

Alanzi AR, Alsalhi MS, Mothana RA, Alqahtani JH, Alqahtani MJ. Insilico discovery of novel Phosphodiesterase 4 (PDE4) inhibitors for the treatment of psoriasis: Insights from computer aided drug design approaches. PLOS ONE. 2024. doi:10.1371/journal.pone.0305934

BibTeX
@article{Alanzi2024,
  author = {Alanzi, Abdullah R and Alsalhi, Mohammed S and Mothana, Ramzi A and Alqahtani, Jawaher H and Alqahtani, Moneerah J},
  title = {Insilico discovery of novel Phosphodiesterase 4 (PDE4) inhibitors for the treatment of psoriasis: Insights from computer aided drug design approaches},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0305934}
}
Kostenlos starten →